Xcout Intel
MDI Therapeutics, Inc.
MDI Therapeutics, Inc. is a pharmaceutical company headquartered in Novi, Michigan. The company specializes in researching and developing novel therapeutics for the treatment of fibrosis and related fibrotic diseases.
Subscribe to see MDI Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MDI Therapeutics, Inc. at a glance
MDI Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $3.2M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round raised $1.7M in February 2022. Xcout tracks 7 named people at MDI Therapeutics, Inc., including Gillian Dines (CEO).
MDI Therapeutics, Inc. leadership
- Gillian DinesCEO
- Mark WeinbergChief Medical Officer
- Daniel A LawrenceFounder/Chairman, Clinical & Scientific Advisory Board
- Grazia PiizziDr. Grazia Piizzi, PhD
- Laurie McFetridgeLaurie McFetridge
- Stephen BenoitStephen Benoit
1 more named person on record for MDI Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
MDI Therapeutics, Inc. funding rounds
At least $3.2M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $1.7M | — | |
| SEC Form D filing | $1.6M | — | |
| Seed | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
MDI Therapeutics, Inc. competitors
A few of MDI Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Endeavor BioMedicines, Inc. is a San Diego-based biotechnology company focused on developing novel treatments for conditions such as fibrosis.
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company located in Mission Viejo, California, focused on developing a platform of compounds for biodefense and fibrosis applications.
Get MDI Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MDI Therapeutics, Inc. in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access